Carmot Therapeutics, Inc. clinical trials
Acquired by Hoffmann-La Roche
The registry lists 7 studies whose lead sponsor is Carmot Therapeutics, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 28, 2026.
- 7studies on the registry
- 0open to participants now
What it is testing
The drugs Carmot Therapeutics, Inc.’s studies test, most studies first; none is open now — 2 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
What changed recently
From the registry's own updates since Oct 20, 2026.
Results posted1
- A Study of CT-868 in Type 1 Diabetes MellitusOct 28, 2026NCT06062069
All 7 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed7100%
Over the years
- 221
- 22
- 23
- 24
- 25
- 026
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Carmot Therapeutics, Inc.7 studies
Something wrong with this grouping? Tell us on the Hoffmann-La Roche page.
Studies
Recruiting first, then most recently updated. Showing 7 of 7. All Hoffmann-La Roche studies →
- A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusCompletedNCT06628362Phase 2
Sponsor listed in the registry: Carmot Therapeutics, Inc. · Carmot Therapeutics, Inc. — acquired company within the Hoffmann-La Roche group
- A Study of CT-868 in Type 1 Diabetes MellitusCompletedNCT06062069Phase 2
Sponsor listed in the registry: Carmot Therapeutics, Inc. · Carmot Therapeutics, Inc. — acquired company within the Hoffmann-La Roche group
- A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityCompletedNCT06525935Phase 2
Sponsor listed in the registry: Carmot Therapeutics, Inc. · Carmot Therapeutics, Inc. — acquired company within the Hoffmann-La Roche group
- A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes MellitusCompletedNCT05110846Phase 2
Sponsor listed in the registry: Carmot Therapeutics, Inc. · Carmot Therapeutics, Inc. — acquired company within the Hoffmann-La Roche group
- A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes MellitusCompletedNCT04838405Phase 1
Sponsor listed in the registry: Carmot Therapeutics, Inc. · Carmot Therapeutics, Inc. — acquired company within the Hoffmann-La Roche group
- A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood GlucoseCompletedNCT04973111Phase 1
Sponsor listed in the registry: Carmot Therapeutics, Inc. · Carmot Therapeutics, Inc. — acquired company within the Hoffmann-La Roche group
- A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 DiabetesCompletedNCT05794581Phase 1
Sponsor listed in the registry: Carmot Therapeutics, Inc. · Carmot Therapeutics, Inc. — acquired company within the Hoffmann-La Roche group